DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms

A method, consisting of:

• obtaining a sample comprising genomic DNA from a subject at risk of acquiring or suspected to have an adrenocortical tumor;
• isolating genomic DNA from the sample;
• and
• measuring a level of methylation in one or more genomic CpG dinucleotide sequences within one or more of malignant adrenocortical tumor-related molecules in genomic DNA isolated sample obtained from the subject at risk of acquiring or suspected to have an adrenocortical tumor,
• wherein the one or more malignant adrenocortical tumor-related molecules comprise at least one of SLC16A9, IL13RA2, HTR2B, CCNB2, RARRES2, KCTD12, KIRREL, SYNGR1 or NTNG2;
• and
• providing a therapeutic regimen based on the one or more methylated genomic CpG dinucleotide sequences.

A method, consisting of:

• obtaining a sample comprising genomic DNA from a subject at risk of acquiring or suspected to have an adrenocortical tumor;
• isolating genomic DNA from the sample;
• and
• measuring a level of methylation in one or more genomic CpG dinucleotide sequences within one or more of malignant adrenocortical tumor-related molecules in genomic DNA isolated sample obtained from the subject at risk of acquiring or suspected to have an adrenocortical tumor,
• wherein the one or more malignant adrenocortical tumor-related molecules comprise at least one of SLC16A9, IL13RA2, HTR2B, CCNB2, RARRES2, KCTD12, KIRREL, SYNGR1 or NTNG2;
• and
• contacting the isolated genomic DNA with sodium bisulfite prior to measuring the level of methylation in one or more genomic CpG dinucleotide sequences.

A method, consisting of:

• obtaining a sample comprising genomic DNA from a subject at risk of acquiring or suspected to have an adrenocortical tumor;
• isolating genomic DNA from the sample;
• and
• measuring a level of methylation in one or more genomic CpG dinucleotide sequences within one or more of malignant adrenocortical tumor-related molecules in genomic DNA isolated sample obtained from the subject at risk of acquiring or suspected to have an adrenocortical tumor,
• wherein the one or more malignant adrenocortical tumor-related molecules comprise at least one of SLC16A9, IL13RA2, HTR2B, CCNB2, RARRES2, KCTD12, KIRREL, SYNGR1 or NTNG2;
• and
• contacting the isolated genomic DNA with sodium bisulfite prior to measuring the level of methylation in one or more genomic CpG dinucleotide sequences;
• and amplifying the sodium bisulfite treated genomic DNA.

A method, consisting of:

• obtaining a sample comprising genomic DNA from a subject at risk of acquiring or suspected to have an adrenocortical tumor;
• isolating genomic DNA from the sample;
• and
• measuring a level of methylation in one or more genomic CpG dinucleotide sequences within one or more of malignant adrenocortical tumor-related molecules in genomic DNA isolated sample obtained from the subject at risk of acquiring or suspected to have an adrenocortical tumor,
• wherein the one or more malignant adrenocortical tumor-related molecules comprise at least one of SLC16A9, IL13RA2, HTR2B, CCNB2, RARRES2, KCTD12, KIRREL, SYNGR1 or NTNG2;
• and
• administering to the subject an effective amount of a demethylating agent that alters activity and/or expression of one or more malignant adrenocortical tumor molecules, thereby treating a malignant adrenocortical tumor.